SNPHFライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (20 4月 2024 @ 03:03):

Stats
本日の出来高	31.00
平均出来高	42.00
時価総額	3.37B
EPS	$24.13 ( 2023-11-06 )
Last Dividend	$0.121 ( 2023-03-30 )
Next Dividend	$0 ( N/A )
P/E	19.29
ATR14	$0 (0.00%)

Santen Pharmaceutical 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Santen Pharmaceutical 財務諸表

Annual	2023
収益:	$279.04B
総利益:	$166.09B (59.52 %)
EPS:	$-38.58

FY	2023
収益:	$279.04B
総利益:	$166.09B (59.52 %)
EPS:	$-38.58

FY	2022
収益:	$266.26B
総利益:	$156.59B (58.81 %)
EPS:	$68.07

FY	2021
収益:	$249.61B
総利益:	$151.38B (60.65 %)
EPS:	$17.09

Financial Reports:

No articles found.

Santen Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.111 (N/A)	$0 (N/A)	$0.121 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Santen Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.85 - Stable (3.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0980	2014-03-27
Last Dividend	$0.121	2023-03-30
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$2.40	--
Avg. Dividend % Per Year	0.00%	--
Score	3.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.85
Div. Directional Score	7.99	--

Next Divdend (Est)
(2024-09-23)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
UOVEY	Ex Dividend Knight	2023-08-04	Annually	0.00%
KNRRY	Ex Dividend Knight	2023-05-08	Annually	0.00%
CCOEF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
SBNC	Ex Dividend Junior	2023-08-31	Quarterly	0.00%
FQVLF	Ex Dividend Junior	2023-08-25	Annually	0.00%
ACCYY	Ex Dividend Knight	2023-05-23	Sporadic	0.00%
XNGSY	Ex Dividend Junior	2023-11-02	Annually	0.00%
MKKGY	Ex Dividend Knight	2023-05-02	Annually	0.00%
CNLPL	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
SRCU	Ex Dividend Junior	2023-08-14	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0918	1.500	8.16	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0648	1.200	7.84	9.41	[0 - 0.3]
returnOnEquityTTM	0.0924	1.500	-0.0848	-0.127	[0.1 - 1]
payoutRatioTTM	0.429	-1.000	5.71	-5.71	[0 - 1]
currentRatioTTM	2.46	0.800	2.72	2.17	[1 - 3]
quickRatioTTM	1.841	0.800	3.88	3.10	[0.8 - 2.5]
cashRatioTTM	0.897	1.500	6.13	9.19	[0.2 - 2]
debtRatioTTM	0.0786	-1.500	8.69	-10.00	[0 - 0.6]
interestCoverageTTM	20.13	1.000	3.66	3.66	[3 - 30]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.113	-1.500	9.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.606	1.000	3.24	3.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.143	1.000	9.14	9.14	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.706	0.800	8.63	6.90	[0.5 - 2]
Total Score				11.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.69	1.000	8.21	0	[1 - 100]
returnOnEquityTTM	0.0924	2.50	-0.0545	-0.127	[0.1 - 1.5]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0150	1.500	9.63	0	[0 - 0.4]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.429	1.500	5.71	-5.71	[0 - 1]
pegRatioTTM	-0.000754	1.500	-3.34	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.225	1.000	6.86	0	[0.1 - 0.5]
Total Score				4.85

Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.